Binge Eating Disorder

Current Binge Eating Disorder News & Information

0

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for ... - Stockhouse

LCS Therapeutics and Lucerne Biosciences to Commercialize ‘813 Patent for …
Stockhouse
8,318,813 entitled “Method of Treating Binge Eating Disorder.” Patent ‘813 features claims that encompass the use of the amphetamine prodrug lisdexamfetamine dimesylate (l-lysine-d-amphetamine) alone, or in combination with other pharmacologic …

and more …read more

bingeatingdisorder.com • December 26, 2014


Previous Post

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for ... - Stockhouse

Next Post

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for ... - Stockhouse